Finding new biomarkers for biliary tract cancer and gallbladder cancer
Identification of New Biomarkers for Patients With Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer) - do They Provide New Information Regarding Diagnosis, Treatment Efficacy, Side Effects, or Prognosis?
This study is trying to find new markers in blood and tissue samples from patients with biliary tract and gallbladder cancer to help doctors diagnose the disease earlier and predict how well treatments will work.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Herlev and Gentofte Hospital Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Herlev, Copenhagen) |
| Trial ID | NCT05184400 on ClinicalTrials.gov |
What this trial studies
This observational study aims to identify new diagnostic, prognostic, and predictive biomarkers for biliary tract cancer (BTC), which includes cholangiocarcinoma and gallbladder cancer. Given the poor prognosis associated with BTC, the study will collect biological materials such as blood samples and tissue from patients undergoing standard or protocolized treatment. The goal is to enhance early diagnosis, improve prognostication, and predict treatment efficacy through the analysis of these biomarkers. Patients will be monitored throughout their treatment journey to assess the effectiveness of the identified biomarkers.
Who should consider this trial
Good fit: Ideal candidates include patients with a confirmed histological or cytological diagnosis of biliary tract cancer who are referred for treatment.
Not a fit: Patients without a diagnosis of biliary tract cancer or those not seeking treatment may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier diagnosis and better treatment outcomes for patients with biliary tract cancer.
How similar studies have performed: While there is limited success with similar approaches, this study aims to explore novel biomarkers that have not been validated in routine clinical practice.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Histological or cytological diagnosis of BTC * Patients referred for treatment of BTC * Signed informed consent Exclusion Criteria: * None
Where this trial is running
Herlev, Copenhagen
- Herlev & Gentofte Hospital — Herlev, Copenhagen, Denmark (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.